1h Free Analyst Time
The publisher has been monitoring the Krabbe disease treatment market and it is poised to grow by $438.03 mn during 2022-2026, accelerating at a CAGR of 7.56% during the forecast period. The report on the Krabbe disease treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by special drug designation, unmet clinical needs, and the practice of consanguineous marriage.
The Krabbe disease treatment market analysis includes the therapy segment and geographic landscape.
The Krabbe disease treatment market is segmented as below:
By Therapy
- Anticonvulsants
- Muscle relaxants
- HSCT
- Others
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the emergence of pharmacological chaperone therapy as one of the prime reasons driving the Krabbe disease treatment market growth during the next few years. Also, gene technology in therapy and an increasing degree of awareness about Krabbe disease will lead to sizable demand in the market.
The report on the Krabbe disease treatment market covers the following areas:
- Krabbe disease treatment market sizing
- Krabbe disease treatment market forecast
- Krabbe disease treatment market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Krabbe disease treatment market vendors that include AbbVie Inc., Acorda Therapeutics Inc., CENTOGENE NV, GlaxoSmithKline Plc, Johnson and Johnson, Novartis AG, Pfizer Inc., Polaryx, Teva Pharmaceutical Industries Ltd., and UCB SA. Also, the Krabbe disease treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Therapy
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global Krabbe disease treatment market: AbbVie Inc., Acorda Therapeutics Inc., CENTOGENE NV, GlaxoSmithKline Plc, Johnson and Johnson, Novartis AG, Pfizer Inc., Polaryx, Teva Pharmaceutical Industries Ltd., and UCB SA.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is the emergence of pharmacological chaperone therapy.`
According to the report, one of the major drivers for this market is the special drug designation.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Acorda Therapeutics Inc.
- CENTOGENE NV
- GlaxoSmithKline Plc
- Johnson and Johnson
- Novartis AG
- Pfizer Inc.
- Polaryx
- Teva Pharmaceutical Industries Ltd.
- UCB SA